948 related articles for article (PubMed ID: 17576169)
21. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
22. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
23. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y
Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769
[TBL] [Abstract][Full Text] [Related]
25. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice.
Lee JW; Kobayashi Y; Nakamichi Y; Udagawa N; Takahashi N; Im NK; Seo HJ; Jeon WB; Yonezawa T; Cha BY; Woo JT
Biochem Pharmacol; 2010 Aug; 80(3):352-61. PubMed ID: 20412788
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
[TBL] [Abstract][Full Text] [Related]
27. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
Huang H; Chang EJ; Ryu J; Lee ZH; Lee Y; Kim HH
Biochem Biophys Res Commun; 2006 Dec; 351(1):99-105. PubMed ID: 17052691
[TBL] [Abstract][Full Text] [Related]
28. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
30. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation.
Negishi-Koga T; Takayanagi H
Immunol Rev; 2009 Sep; 231(1):241-56. PubMed ID: 19754901
[TBL] [Abstract][Full Text] [Related]
31. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
[TBL] [Abstract][Full Text] [Related]
32. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
33. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
[TBL] [Abstract][Full Text] [Related]
34. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
[TBL] [Abstract][Full Text] [Related]
35. Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.
Komano Y; Nanki T; Hayashida K; Taniguchi K; Miyasaka N
Arthritis Res Ther; 2006; 8(5):R152. PubMed ID: 16987426
[TBL] [Abstract][Full Text] [Related]
36. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway.
Lee MS; Kim HS; Yeon JT; Choi SW; Chun CH; Kwak HB; Oh J
J Immunol; 2009 Sep; 183(5):3390-9. PubMed ID: 19641137
[TBL] [Abstract][Full Text] [Related]
37. Expression profile of RhoGTPases and RhoGEFs during RANKL-stimulated osteoclastogenesis: identification of essential genes in osteoclasts.
Brazier H; Stephens S; Ory S; Fort P; Morrison N; Blangy A
J Bone Miner Res; 2006 Sep; 21(9):1387-98. PubMed ID: 16939397
[TBL] [Abstract][Full Text] [Related]
38. Regulation of human osteoclast differentiation by thioredoxin binding protein-2 and redox-sensitive signaling.
Aitken CJ; Hodge JM; Nishinaka Y; Vaughan T; Yodoi J; Day CJ; Morrison NA; Nicholson GC
J Bone Miner Res; 2004 Dec; 19(12):2057-64. PubMed ID: 15537450
[TBL] [Abstract][Full Text] [Related]
39. RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways.
Nakao A; Fukushima H; Kajiya H; Ozeki S; Okabe K
Biochem Biophys Res Commun; 2007 Jun; 357(4):945-50. PubMed ID: 17467668
[TBL] [Abstract][Full Text] [Related]
40. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.
Kim JH; Kim K; Youn BU; Jin HM; Kim N
Cell Signal; 2010 Sep; 22(9):1341-9. PubMed ID: 20466061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
